|
FY2025
12 months to Sep 30, 2025
|
FY2024
12 months to Sep 30, 2024
|
FY2023
12 months to Sep 30, 2023
|
FY2022
12 months to Sep 30, 2022
|
|
|---|---|---|---|---|
| Non-cash items: | ||||
| Depreciation – right-of-use asset | ||||
| Foreign exchange | ||||
| Interest expense | ||||
| Share-based compensation | ||||
| Shares recorded as consulting fees | ||||
| Shares recorded as research and development | ||||
| Impairment of intangible assets | ||||
| Changes in non-cash working capital items: | ||||
| Sales tax receivables | ||||
| Interest and other receivables | ||||
| Prepaids | ||||
| Accounts payable and accrued liabilities | ||||
| Net cash used in operating activities | ||||
| Financing activities | ||||
| Finder's fees | ||||
| Private placement proceeds | ||||
| Share issuance costs | ||||
| Special warrant proceeds | ||||
| Refund of special warrant proceeds | ||||
| Pre funded warrant exercise proceeds | ||||
| Warrant exercise proceeds | ||||
| Compensation warrant exercise proceeds | ||||
| Pre-funded warrant issuance proceeds | ||||
| Option exercise proceeds | ||||
| Pre-funded warrant and warrant exercise proceeds | ||||
| Principal portion of lease liability | ||||
| Net cash from financing activities | ||||
| Change in cash and cash equivalents | ||||
| Change in cash and cash equivalents | ||||
| Effect of foreign exchange on cash | ||||
| Cash and cash equivalents, beginning of year | ||||
| Cash and cash equivalents, end of year | ||||
| SUPPLEMENTARY INFORMATION | ||||
| Debt settlement by issuing shares | ||||
| Fair value ascribed by brokers' warrants issued | ||||
| Fair value of options issued as finder's fees | ||||
| Fair value of RSUs exercised | ||||
| Fair value of Pre-funded warrants exercised | ||||
| Fair value of options exercised | ||||
| Share issuance costs included in accounts payable and accrued liabilities | ||||
Loading...
